---
company: MOLINA HEALTHCARE, INC.
ticker: MOH
form: 8-K
filed: 2026-10-21
accession: 0001179929-26-000042
source: https://www.sec.gov/Archives/edgar/data/1179929/000117992926000042/
---

# Molina Healthcare (MOH) earnings release, October 21, 2026

Molina Healthcare, Inc. (MOH) · Form 8-K, Item 2.02 · Filed 2026-10-21 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1179929/000117992926000042/)

News Release

Investor Contact:

Jeffrey Geyer,

Jeffrey.Geyer@molinahealthcare.com, 305-317-3012

Media Contact:

Caroline Zubieta,

Caroline.Zubieta@molinahealthcare.com, 562-542-1845

Molina Healthcare Reports Third Quarter 2026 Financial Results

Reaffirms Full Year 2026 Earnings Guidance

Long Beach, Calif., October 21, 2026 – Molina Healthcare, Inc. (NYSE: MOH) (the “Company”) today reported third quarter 2026 GAAP income per diluted share of $0.73 and adjusted income per diluted share of $0.89. Financial results are summarized below:

Quarter Highlights

• As of September 30, 2026, the Company served approximately 4.9 million members.

• Premium revenue was approximately $10.5 billion for the third quarter of 2026.

• Third quarter 2026 GAAP income per diluted share was $0.73 and adjusted income per diluted share was $0.89.

• The Company reaffirmed its full year 2026 guidance of expected premium revenue of approximately $42 billion and adjusted earnings of at least $5.25 per diluted share.

“We are pleased with our third quarter results in this challenging environment and reaffirm our full year guidance,” said Joseph Zubretsky, President and Chief Executive Officer. “With the apparent plateauing of medical cost trend, which remains at elevated levels, and the strength of recent rate updates for 2027, we believe we are likely observing the beginning of the turn in Medicaid margins.”

-MORE-

Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results

Page 2

October 21, 2026

Premium Revenue

Premium revenue was approximately $10.5 billion for the third quarter of 2026, a decrease of 4% year over year. The lower premium revenue reflects the impact of lower membership in Medicaid and Marketplace, partially offset by rate updates.

Net Income

GAAP net income for the third quarter of 2026 was $38 million, or $0.73 per diluted share, a decrease of 52% year over year. Adjusted net income for the third quarter of 2026 was $46 million, or $0.89 per diluted share, a decrease of 53% year over year. The decrease is attributed mainly to a higher consolidated MCR.

Medical Care Ratio (MCR)

• The consolidated MCR for the third quarter of 2026 was 92.9%.

• The Medicaid MCR for the third quarter of 2026 was 93.0% and in line with the Company’s expectations, reflecting rate updates and stable medical cost trend.

• The Medicare MCR for the third quarter of 2026 was 93.0% and in line with the Company’s expectations, reflecting stable medical cost trend.

• The Marketplace MCR for the third quarter of 2026 was 92.5% and in line with normal seasonality and the Company’s expectations.

General and Administrative Expense Ratio

The G&A ratio and the adjusted G&A ratio for the third quarter of 2026 were 6.4% and 6.3%, respectively, reflecting continued operating discipline.

Balance Sheet

Cash and investments at the parent company were approximately $608 million as of September 30, 2026, compared to $223 million as of December 31, 2025.

Days in claims payable at September 30, 2026, was 44, consistent with June 30, 2026.

Cash Flow

Operating cash flow for the nine months ended September 30, 2026, was $629 million, compared to an outflow of $237 million for the nine months ended September 30, 2025. The increase compared to the prior year was driven mainly by lower government receivable and payable settlements in 2026.

2026 Guidance

Premium revenue guidance for the full year is unchanged at approximately $42 billion.

The Company expects its full year 2026 GAAP earnings to be at least $2.38 per diluted share and reaffirmed its full year 2026 adjusted earnings of at least $5.25 per diluted share. Guidance metrics across all segments are also reaffirmed. Full year earnings guidance includes a loss of $1.50 per share due to the implementation of the new Florida Medicaid contract in the fourth quarter of 2026 and a loss of $1.00 per share due to performance of the traditional MAPD product, which the Company previously announced it will exit for 2027.

-MORE-

Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results

Page 3

October 21, 2026

Conference Call

Management will host a conference call and webcast to discuss Molina Healthcare’s third quarter ended September 30, 2026 results, at 8:00 a.m. Eastern Time on Thursday, October 22, 2026. The number to call for the interactive teleconference is (877) 883-0383 and the confirmation number is 6534841. A telephonic replay of the conference call will be available through Thursday, October 29, 2026, by dialing (855) 669-9658 and entering confirmation number 4361465.

A live audio broadcast of this conference call will be available on Molina Healthcare’s investor relations website, investors.molinahealthcare.com. A 30-day online replay will be available approximately an hour following the conclusion of the live broadcast.

About Molina Healthcare

Molina Healthcare, Inc., a FORTUNE 500 company, provides managed healthcare services under the Medicaid and Medicare programs and through the state insurance marketplaces. For more information about Molina Healthcare, please visit molinahealthcare.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995... (truncated)th,” “intends,” “plans,” “predicts,” “projects,” “will,” “would,” “could,” “can,” “may,” or the negative of these terms or other similar expressions. Forward-looking statements contained in this earnings release include, but are not limited to, statements regarding the Company’s 2026 guidance and long-term performance outlook, trends with respect to rates, pretax margins, utilization, and medical costs, including the timing thereof and the anticipated impact on the Company’s business, and our management’s plans and objectives for future operations and business strategy.

Actual results could differ materially due to numerous known and unknown risks and uncertainties. These risks and uncertainties are discussed under the headings “Forward-Looking Statements,” and “Risk Factors,” in the Company’s Annual Report on Form 10‑K for the year ended December 31, 2025, which is on file with the U.S. Securities and Exchange Commission (the “SEC”), and in the Company’s other filings with the SEC, including its Quarterly Reports on Form 10-Q for the period ended March 31, 2026 and June 30, 2026 filed with the SEC and Quarterly Report on Form 10-Q for the period ended September 30, 2026, to be filed with the SEC.

These reports can be accessed under the investor relations tab of the Company’s website or on the SEC’s website at sec.gov. Given these risks and uncertainties, the Company can give no assurances that its forward-looking statements will prove to be accurate, or that any other results or developments projected or contemplated by its forward-looking statements will in fact occur, and the Company cautions investors not to place undue reliance on these statements. All forward-looking statements in this release represent the Company’s judgment as of October 21, 2026, and, except as otherwise required by law, the Company disclaims any obligation to update any forward-looking statement to conform the statement to actual results or changes in its expectations.

-MORE-

Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results

Page 4

October 21, 2026

## Financial statements

### Income Statement (Three months ended (in millions))

| | Three months ended – September 30, – 2026 | Three months ended – September 30, – 2025 | Nine months ended – September 30, – 2026 | Nine months ended – September 30, – 2025 |
|---|---:|---:|---:|---:|
| Premium Revenue | 10,457 | 10,841 | 30,873 | 32,337 |
| Total Revenue | 11,082 | 11,477 | 32,752 | 34,051 |
| GAAP: | Net Income | 38 | 79 | 112 | 632 |
| GAAP: | EPS – Diluted | 0.73 | 1.51 | 2.19 | 11.79 |
| GAAP: | Medical Care Ratio (MCR) | 92.9 | 92.6 | 92.1 | 90.8 |
| GAAP: | G&A Ratio | 6.4 | 6.4 | 6.8 | 6.5 |
| GAAP: | Pre-tax Margin | 0.5 | 0.8 | 0.5 | 2.4 |
| Adjusted: | Net Income | 46 | 97 | 243 | 724 |
| Adjusted: | EPS – Diluted | 0.89 | 1.84 | 4.74 | 13.49 |
| Adjusted: | G&A Ratio | 6.3 | 6.3 | 6.6 | 6.4 |
| Adjusted: | Pre-tax Margin | 0.6 | 1 | 1.1 | 2.7 |

### Income Statement (Three Months Ended — UNAUDITED CONSOLIDATED STATEMENTS OF INCOME (in millions))

| | Three Months Ended – September 30, – 2026 | Three Months Ended – September 30, – 2025 | Nine Months Ended – September 30, – 2026 | Nine Months Ended – September 30, – 2025 |
|---|---:|---:|---:|---:|
| Revenue: | Premium revenue | 10,457 | 10,841 | 30,873 | 32,337 |
| Revenue: | Premium tax revenue | 500 | 506 | 1,509 | 1,325 |
| Revenue: | Investment income | 102 | 108 | 301 | 322 |
| Revenue: | Other revenue | 23 | 22 | 69 | 67 |
| Revenue: | Total revenue | 11,082 | 11,477 | 32,752 | 34,051 |
| Operating expenses: | Medical care costs | 9,719 | 10,044 | 28,429 | 29,352 |
| Operating expenses: | General and administrative expenses | 710 | 729 | 2,213 | 2,214 |
| Operating expenses: | Premium tax expenses | 500 | 506 | 1,509 | 1,325 |
| Operating expenses: | Depreciation and amortization | 38 | 45 | 117 | 151 |
| Operating expenses: | Impairment |  |  | 93 |  |
| Operating expenses: | Other | 9 | 16 | 57 | 66 |
| Operating expenses: | Total operating expenses | 10,976 | 11,340 | 32,418 | 33,108 |
| Operating expenses: | Operating income | 106 | 137 | 334 | 943 |
| Operating expenses: | Interest expense | 53 | 49 | 161 | 140 |
| Operating expenses: | Income before income tax expense | 53 | 88 | 173 | 803 |
| Operating expenses: | Income tax expense | 15 | 9 | 61 | 171 |
| Operating expenses: | Net income | 38 | 79 | 112 | 632 |
| Operating expenses: | Net income per share – Diluted | 0.73 | 1.51 | 2.19 | 11.79 |
| Operating expenses: | Diluted weighted average shares outstanding | 51.5 | 52.5 | 51.3 | 53.6 |

### Balance Sheet (September 30, — CONSOLIDATED BALANCE SHEETS (in millions))

| | September 30, – 2026 – Unaudited – ASSETS | December 31, – 2025 – ASSETS |
|---|---:|---:|
| Current assets: | Cash and cash equivalents | 4,479 | 4,248 |
| Current assets: | Investments | 4,100 | 4,008 |
| Current assets: | Receivables | 3,359 | 3,533 |
| Current assets: | Prepaid expenses and other current assets | 576 | 655 |
| Current assets: | Total current assets | 12,514 | 12,444 |
| Current assets: | Property, equipment, and capitalized software, net | 324 | 301 |
| Current assets: | Goodwill and intangible assets, net | 2,073 | 2,195 |
| Current assets: | Restricted investments | 345 | 299 |
| Current assets: | Deferred income taxes, net | 267 | 178 |
| Current assets: | Other assets | 129 | 147 |
| Current assets: | Total assets | 15,652 | 15,564 |
| Current liabilities: | Medical claims and benefits payable | 4,988 | 4,887 |
| Current liabilities: | Amounts due government agencies | 1,141 | 1,326 |
| Current liabilities: | Accounts payable, accrued liabilities and other | 1,183 | 1,093 |
| Current liabilities: | Deferred revenue | 82 | 66 |
| Current liabilities: | Total current liabilities | 7,394 | 7,372 |
| Current liabilities: | Long-term debt | 3,771 | 3,766 |
| Current liabilities: | Finance lease liabilities | 179 | 184 |
| Current liabilities: | Other long-term liabilities | 153 | 173 |
| Current liabilities: | Total liabilities | 11,497 | 11,495 |
| Stockholders’ equity: | Additional paid-in capital | 536 | 452 |
| Stockholders’ equity: | Accumulated other comprehensive (loss) income | -95 | 15 |
| Stockholders’ equity: | Retained earnings | 3,714 | 3,602 |
| Stockholders’ equity: | Total stockholders’ equity | 4,155 | 4,069 |
| Stockholders’ equity: | Total liabilities and stockholders’ equity | 15,652 | 15,564 |

### Cash Flow (Nine Months Ended — UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS (in millions))

| | Nine Months Ended – September 30, – 2026 | Nine Months Ended – September 30, – 2025 |
|---|---:|---:|
| Operating activities: | Net income | 112 | 632 |
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: | Depreciation and amortization | 117 | 151 |
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: | Deferred income taxes | -54 | 37 |
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: | Share-based compensation | 85 | 27 |
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: | Impairment | 93 |  |
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: | Other, net | -21 | -2 |
| Changes in operating assets and liabilities: | Receivables | 174 | -118 |
| Changes in operating assets and liabilities: | Prepaid expenses and other current assets | 11 | -25 |
| Changes in operating assets and liabilities: | Medical claims and benefits payable | 101 | -157 |
| Changes in operating assets and liabilities: | Amounts due government agencies | -185 | -467 |
| Changes in operating assets and liabilities: | Accounts payable, accrued liabilities and other | 88 | -195 |
| Changes in operating assets and liabilities: | Deferred revenue | 16 | -44 |
| Changes in operating assets and liabilities: | Income taxes | 92 | -76 |
| Changes in operating assets and liabilities: | Net cash provided by (used in) operating activities | 629 | -237 |
| Investing activities: | Purchases of investments | -1,245 | -607 |
| Investing activities: | Proceeds from sales and maturities of investments | 1,020 | 1,017 |
| Investing activities: | Purchases of property, equipment, and capitalized software | -94 | -102 |
| Investing activities: | Net cash paid in business combinations |  | -245 |
| Investing activities: | Other, net | -9 | 19 |
